Keytruda (pembrolizumab) is prescribed to treat melanoma and other conditions by reviving the body’s immune system. Your response to this drug may vary based on your medical history, diagnosis, and ...
Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements. Patients with advanced non-small cell lung cancer ...
David Chism, MD: For pairing it with the immunotherapy, I would prefer just 1 chemotherapy rather than ...
Work at Aligos Therapeutics Inc. has led to the discovery of new programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the ...
Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo. Disease-free survival (DFS; time after diagnosis during which a person shows ...
CCR5 inhibition combined with ICI therapy increased overall survival in patients with mTNBC, with 18% of heavily pretreated mTNBC patients alive after a median of ~60 months. Inhibition of CCR5 by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback